胰高糖素样肽-1类似物的进展与临床应用评价  

Research Progress and Clinical Utilization Review on Glicagon-like Peptide-1(GLP-1)

作　　者：张石革[1] 苗建伟[1] 

机构地区：[1]北京大学第四临床医学院北京积水潭医院,北京100035

出　　处：《中国医院用药评价与分析》2011年第4期298-301,共4页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:胰高糖素样肽-1类似物的问世为抗糖尿病药宝库中增添了一朵奇葩,其进展神速,作用途径独特,迂回在胰岛β细胞和胰岛素之外,本文总结其作用特点和临床评价。方法:对国内外近期文献进行分析。结果与结论:胰高糖素样肽-1类似物作用确切,在大量的临床研究中显示了良好效果和安全性,为糖尿病者的治疗展现了治疗前景,在延缓或逆转糖尿病自然病程的治疗策略中,为研发抗糖尿病新药提供了更为广阔的空间。OBJECTIVE： The appearance of glicagon like peptide-1（GLP-1） added an exotic flower to antidiabetes drugs,with marvelous advance and distinctive action channel,glicagon like peptide-1 is circuitous beyond pancreatic islet-beta cells and insulin.The aim of this study was to summarize the action characteristics and the clinical use of GLP-1.METHODS： We analyzed the medical literatures in recent years both at home and abroad.RESULTS CONCLUSION： Numerous clinical trials proved the efficacy and safety of glicagon-like peptide-1,which is expected to become a therapy for the treatment of diabetic patients,and it provides a broader space for the development of new antidiabetic drugs in the therapeutic regimen of delaying or reversing the natural course of diabetes.

关 键 词：胰高糖素样肽-1类似物 艾塞那肽 利拉鲁肽 糖尿病 进展 临床评价 

分 类 号：R977.15[医药卫生—药品]